Private equity firms have moved aggressively into the healthcare industry’s more hidden niches: They are pouring billions into the business of clinical drug trials.
After finding success investing in the more obviously lucrative corners of American medicine like surgery centers and dermatology practices private equity firms have moved aggressively into the industry’s more hidden niches: They are pouring billions into the business of clinical drug trials. To bring a new drug to market, the FDA requires pharmaceutical
After finding success investing in the more obviously lucrative corners of American medicine like surgery centers and dermatology practices private equity firms have moved aggressively into the industry's more hidden niches: They are pouring billions into the business of clinical drug trials.
April 22, 2021
published at 12:30 PMglobenewswire
Dyadic International Hosting a Fireside Chat on “The Potential of the Transformative Dyadic C1 Protein Technology in Helping Meet Global Health Challenges”
Fireside Chat Being Held on Tuesday, May 4th @ 10am Eastern Time
GlobeNewswire
April 22, 2021
JUPITER, Fla., April 22, 2021 (GLOBE NEWSWIRE) Dyadic International, Inc. ( Dyadic , we , us , our , or the Company ) (NASDAQ:DYAI), a global biotechnology company focused on developing and deploying its proprietary C1-cell protein production platform to optimize the development of vaccines, therapeutics and other protein based products today announced that it will host a fireside chat on Tuesday, May 4, 2021 at 10:00am Eastern Time. The fireside chat will focus on the potential of the transformative Dyadic C1 protein technology in helping meet global health challenges.
Share:
JUPITER, Fla., April 22, 2021 (GLOBE NEWSWIRE) Dyadic International, Inc. ( Dyadic , we , us , our , or the Company ) (NASDAQ:DYAI), a global biotechnology company focused on developing and deploying its proprietary C1-cell protein production platform to optimize the development of vaccines, therapeutics and other protein based products today announced that it will host a fireside chat on Tuesday, May 4, 2021 at 10:00am Eastern Time. The fireside chat will focus on the potential of the transformative Dyadic C1 protein technology in helping meet global health challenges.
The moderated discussion will include the following Key Opinion Leaders (KOLs):
Alain Townsend, Ph.D. – Weatherall Institute - Oxford University